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Abstract 
    In the present investigation, a series of novel methyl-2-(mercaptomethyl)-3-(2-thienyl) acrylate (6-23) have 
been synthesized. The newly synthesized compounds were characterized by IR, NMR (
1H and 
13C) and mass. 
All the compounds were screened for their antimicrobial activities. Some of these compounds exhibited a wide 
range of activities, from completely inactive to the good active compounds. 
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Introduction 
    Nowadays, microorganisms resistant to multiple antimicrobial agents are serious problems worldwide in the 
fight against infectious diseases, increasing morbidity and mortality with an overall increase in health care 
costs
1-5. For these reasons, there is an -overwhelming need to develop novel antimicrobial agents with difficult 
mechanism of action aimed at a better understanding of antimicrobial resistance. Nitrogen and sulfur 
heterocyclic system families are very interesting due to their versatile pharmacological activities, such as 
antitumour, diuretics, fungicides, bactericides, antihelmintic, antiallergic, anti-ulcer and local analgesic
6-8, 
especially in the sense of design of new drugs.    
    Thiophene nucleus represents a very important field in drug discovery, which is present in many natural and 
synthetic products with a wide range of pharmacological activities
9-17. The various changes in the structure of 
these compounds are worth studying inorder to synthesize less toxic and more potent drugs. In continuation of 
our ongoing interest, we decided to combine the thienyl acrylate with various heterocyclic moieties
18-25   in hope 
that the resulting novel heterocycles would be biologically active. 
          By considering these heterocycles with potential antimicrobial effects, a new series of Thienyl acrylate 
compounds were synthesized via Baylis-Hillman reaction and their antimicrobial properties was evaluated. The 
Baylis-Hillman reaction
26-32 has attracted the attention of organic chemists for preparing synthetically useful 
multifunctional molecules, which have been successfully employed in various synthesis. 
 
Experimental section 
All the chemicals and reagents were procured from Sigma Aldrich lab grade source. All the solvents used 
were from commercial sources and redistilled before use. All melting points were determined on a Buchi 
apparatus and are uncorrected. The Infra red spectra (in KBr pellets) were recorded on a JASCO spectrometer 
and frequencies are expressed in cm
-1. Mass spectra (CG/MS) were recorded on a Agilent MSD VL mass 
spectrometer. 
1H NMR spectra were recorded on a Bruker Advance 400 spectrometer operating at 400.00 MHz 
and 
13C NMR spectra were recorded on a Bruker Advance 300 spectrometer operating at 300.00MHz. The 
chemical shifts are reported in ppm (δ) relative to tetra methyl silane. Proton and carbon spectra were typically 
obtained at room temperature. The purity of the compounds was checked by thin layer chromatography (TLC) 
on silica gel plates using ethyl acetate: hexane or methylene dichloride: methanol as eluent and spots were 
developed in ultraviolet. 
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General Synthetic procedure of methyl (2Z)-2-(bromomethyl)-3-(2-thienyl) acrylate, 4 
      Thiophene-2-carboxaldehyde 1 (0.04 mole), methyl acrylate 2 (0.14 mole) 1,4-diazabicyclo[2.2.2]octane 
(DABCO) (0.04 mole) were stirred at room temperature for 72 h and the reaction was monitored by TLC. Ethyl 
acetate was used to dilute the reaction mixture after the completion of the reaction and washed successively with 
2N HCl, aqueous sodium bicarbonate solution and water. The organic layer was dried over anhydrous sodium 
sulphate and the solvent was evaporated to get crude hydroxy compound 3. To the crude 3, 47% HBr (0.285 
mole) and Con.H2SO4 (0.13 mole) were added and stirred in methylene chloride at 0-10°C for 3 h. The reaction 
mixture was extracted in methylene chloride and washed with sodium bicarbonate solution and water. It was 
then dried, solvent evaporated to get the residue, to obtain a yellow solid which was recrystallised from n-
hexane (9 g) Yield 78 %; m.p. 52 °C. I.R (KBr pellets cm
-1): υ 1710, 1602, 1415, 1214, 1201, 723; 
1H NMR 
(CDCl3, 400 MHz): δ 8.03 (s, 1H), δ 7.64 (d, J = 5 Hz, 1H), δ 7.47 (d, J = 3.6 Hz, 1H), δ 7.18 (dd, J = 3.96, 5.08 
Hz, 1H), δ 4.59 (s, 2H), δ 3.87 (s, 3H); 
13C NMR (300 MHz, DMSO-d6): δ 166.02, 136.11, 135.78, 135.28, 
133.96, 128.27, 123.57, 52.43, 27.91. 
 
General Synthetic procedure for methyl (2E)-2-[(pyridin-2-ylthio) methyl]-3-(2-thienyl) acrylate, 6 
      Compound 4 (0.002 mole) was treated with 2-mercapto pyridine (0.002 mole) in the presence of Na2CO3 in 
methanol for 1 h at room temperature. Water was added to the reaction mixture which precipitates out the solid 
was filtered and purified in methanol to get pure compound as yellow solid. Yield 56%; m.p. 80 °C. I.R (KBr 
pellets cm
-1): υ 1706, 1608, 1411, 1265, 1201, 1120, 721 ppm; 
1H NMR (DMSO-d6, 400 MHz): δ 8.46 (d, J = 
4.28 Hz, 1H), δ 7.97 (s, 1H), δ 7.90 (d, J = 4.96 Hz, 1H), δ 7.68- δ 7.62  (m, 2H), δ 7.35 (d, J = 8.32 Hz, 1H), δ 
7.37 (m, 1H), 7.17 (dd, J = 5.0, 7.16 Hz, 1H), δ 7.22 (t, 1H), δ 4.43 (s, 2H), δ 3.75 (s, 3H); 
13C NMR (300 MHz, 
DMSO-d6): δ 166.81, 158.09, 149.35, 136.56, 134.52, 134.21, 132.42, 127.81, 122.42, 121.71, 119.87, 52.18, 
27.74; MS: m/z 292.1 (M
+). 
 
   Methyl (2E)-2-[(pyrimidin-2-ylthio) methyl]-3-(2-thienyl) acrylate, 7: Brown solid. Yield 58%; m.p. 98 
°C. I.R (KBr pellets cm
-1): υ 1710, 1610, 1380, 1263, 1199, 727 ppm; 
1H NMR (DMSO-d6, 400 MHz): δ 8.67 
(d, J = 4.88 Hz, 2H), δ 8.0 (s, 1H), δ 7.91 (d, J = 5.04 Hz, 1H), δ 7.64 (d, J = 3.48 Hz, 1H), δ 7.28 (t, 1H), δ 7.23 
(t, 1H), δ 4.44 (s, 2H), δ 3.74 (s, 3H); 
13C NMR (300 MHz, DMSO-d6): δ 170.72, 166.77, 157.76 (2C), 136.47, 
134.82, 134.62, 132.59, 127.86, 121.64, 117.35, 52.24, 28.53; MS: m/z 293.1 (M
+). 
 
   Methyl(2E)-2-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)methyl]-3-(2-thienyl) acrylate, 8: Yellow solid. 
Yield 55%; m.p. 141 °C. I.R (KBr pellets cm
-1): υ 1702, 1606, 1563, 1267, 1207, 858 ppm; 
1H NMR (DMSO-
d6, 400 MHz): δ 14.14 (bs, 1H), δ 8.78 (s, 1H), δ 8.30 (s, 2H), δ 8.06 (s, 1H), δ 7.92 (d, J = 4.96 Hz, 1H), δ 7.68 
(d, J = 3.56 Hz, 1H), δ 7.24 (t, 1H), δ 4.69 (s, 2H), δ 3.77 (s, 3H); 
13C NMR (300 MHz, DMSO-d6): δ 166.81, 
163.82, 154.01, 152.19, 136.49, 135.22, 135.15, 132.95, 132.25, 128.09, 121.32, 110.83, 52.44, 26.86; MS: m/z 
333.1 (M
+). 
 
   Methyl  (2E)-2-{[(1-methyl-1H-imidazol-2-yl)thio]methyl}-3-(2-thienyl) acrylate, 9: Brown solid. Yield 
68%; m.p. 134 °C. I.R (KBr pellets cm
-1): υ 1708, 1627, 1397, 1271, 1209, 1151, 702 ppm; 
1H NMR (DMSO-
d6, 400 MHz): δ 7.90 (d, J = 4.28 Hz, 2H), δ 7.57 (s, 1H), δ 7.25 (d, J = 1.0 Hz, 1H), δ 7.20 (s, 1H), δ 6.92 (d, J 
= 1.12 Hz, 1H), δ 4.13 (s, 2H), δ 3.67 (s, 3H), δ 3.61 (s, 3H); 
13C NMR (300 MHz, DMSO-d6): δ 166.59, 
138.48, 136.51, 134.35, 135.55, 132.08, 128.84, 127.85, 123.78, 123.30, 52.16, 33.06, 32.15; MS: m/z 295.1 
(M
+). 
 
   Methyl(2E)-2-[(1H-benzimidazol-2-ylthio)methyl]-3-(2-thienyl) acrylate, 10: White solid. Yield 72%; m.p. 
160 °C. I.R (KBr pellets cm
-1): υ 1737, 1616, 1440, 1278, 1213, 736 ppm; 
1H NMR (DMSO-d6, 400 MHz): δ 
7.99 (s, 1H), δ 7.87 (d, J = 5.0 Hz, 1H), δ 7.64 (d, J = 3.24 Hz, 1H), δ 7.41 (d, J = 3.84 Hz, 2H), δ 7.56 (t, 1H), δ 
7.03 (d, J = 3.52 Hz, 2H), δ 4.53 (s, 2H), δ 3.77 (s, 3H); 
13C NMR (300 MHz, DMSO-d6): δ 167.0, 149.27, 
136.29, 134.81, 134.71, 132.79, 127.98, 127.31, 126.05, 125.60, 122.17, 121.80, 121.33, 113.89, 52.52, 29.60; 
MS: m/z 331.1 (M
+). 
 
   Methyl(2E)-2-{[(5-methoxy-1H-benzimidazol-2-yl)thio]methyl}-3-(2-thienyl)  acrylate,  11:  White solid. 
Yield 75%; m.p. 165 °C. I.R (KBr pellets cm
-1): υ 1705, 1614, 1273, 1206, 1154, 1027, 834, 710 ppm; 
1H NMR 
(DMSO-d6, 400 MHz): δ 7.99 (s, 1H), δ 7.90 (d, J = 4.88 Hz, 1H), δ 7.65 (d, J = 3.84 Hz, 1H), δ 7.35 (s, 1H), δ 
7.23 (t, 1H), δ 6.97 (d, J = 13.6 Hz, 1H), δ 6.74 (t, 1H), δ 4.51 (s, 2H), δ 3.77 (s, 3H), δ 3.75 (s, 3H); 
13C NMR 
(300 MHz, DMSO-d6 ): δ 166.73, 155.42, 136.50, 135.54, 134.91, 134.75, 132.83, 128.04, 126.54, 125.35, 
122.05, 110.55, 67.30, 55.45, 52.33, 29.98, 22.81; MS: m/z 361.1 (M
+). 
 
    Methyl(2E)-2-({[5-(difluoromethoxy)-1H-benzimidazol-2-yl]thio}methyl)-3-(2-thienyl) acrylate, 12: 
Yellow solid. Yield 79%; m.p. 161 °C. I.R (KBr pellets cm
-1): υ 1738, 1618, 1435, 1119, 1038, 708 ppm; 
1H 
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NMR (DMSO-d6, 400 MHz): δ 12.79 (s, 1H), δ 8.02 (s, 1H), δ 7.93 (d, J = 4.96 Hz, 1H), δ 7.67 (d, J = 3.36 Hz, 
1H), δ 7.23 - δ 7.18 (m, 4H), δ 6.99 (d, J = 7.72 Hz, 1H), δ 4.57 (s, 2H), δ 3.74 (s, 3H); 
13C NMR (300 MHz, 
CDCl3): δ 1669.25, 143.21, 136.94, 135.71, 133.85, 131.58, 127.94, 126.85, 125.82, 122.97, 118.75, 116.49, 
115.45, 114.79, 101.36, 53.88, 30.61; MS: m/z 397.0 (M
+). 
 
   Methyl  (2E)-2-{[(5-nitro-1H-benzimidazol-2-yl)thio]methyl}-3-(2-thienyl) acrylate, 13: Brown solid. 
Yield 70%; m.p. 176 °C. I.R (KBr pellets cm
-1): υ 1691, 1610, 1405, 1280, 1209, 835, 703 ppm;  
1H NMR 
(DMSO-d6, 400 MHz): δ 8.09 (d, J = 2.04 Hz, 1H), δ 7.93 (s, 1H), δ 7.88 (d, J = 4.84 Hz, 1H), δ 7.75 (dd, J = 
2.04, 8.56 Hz, 1H), δ 7.67 (d, J = 3.36 Hz, 1H), δ 7.24 - δ 7.18 (m, 2H), δ 4.53 (s, 2H), δ 3.76 (s, 3H); 
13C NMR 
(300 MHz, DMSO-d6 ): δ 175.95, 153.90, 136.77, 133.97, 133.68, 132.19, 127.84, 127.48, 126.40, 125.95, 
123.47, 113.55, 112.73, 109.80, 52.55, 28.93; MS: m/z 376.0 (M
+). 
 
   Methyl(2E)-2-{[(5-methyl-1H-benzimidazol-2-yl)thio]methyl}-3-(2-thienyl) acrylate, 14: Brown solid. 
Yield 78%; m.p. 140 °C. I.R (KBr pellets cm
-1): υ 1737, 1616, 1436, 1274, 1205, 806, 705 ppm; 
1H NMR 
(DMSO-d6, 400 MHz): δ 8.01 (s, 1H), δ 7.92 (d, J = 5.04 Hz, 1H), δ 7.67 (d, J = 3.64 Hz, 1H), δ 7.36 (d, J = 
8.04 Hz, 1H), δ 7.26 - δ 7.21 (m, 2H), δ 6.99 (d, J = 8.2 Hz, 1H), δ 4.55 (s, 2H), δ 3.72 (s, 3H), δ 2.39 (s, 3H); 
13C NMR (300 MHz, CDCl3):  δ 169.29, 144.58, 135.88, 133.33, 132.51, 131.83, 127.85, 126.28, 125.70, 
124.23, 123.16, 118.12, 109.01, 108.57, 53.45, 23.29, 21.69; MS: m/z 345.1 (M
+). 
 
   Methyl(2E)-2-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-3-(2-thienyl) acrylate, 15: White solid. Yield 
77%; m.p. 142 °C. I.R (KBr pellets cm
-1) υ 1702, 1627, 1398, 1270, 1209 ppm;
1H NMR (DMSO-d6, 400 MHz): 
δ 8.04 (s, 1H), δ 7.97 (d, J = 5.04 Hz, 1H), δ 7.66 (d, J = 3.48 Hz, 1H), δ 7.25 (dd, J = 3.92, 4.8 Hz, 1H), δ 4.53 
(s, 2H), δ 3.76 (s, 3H), δ 2.70 (s, 3H); 
13C NMR (300 MHz, DMSO-d6 ): δ 166.45, 166.0, 152.86, 136.16, 
135.13, 134.83, 132.84, 128.06, 121.58, 52.28, 51.02, 31.27; MS: m/z 313.0 (M
+). 
 
   Methyl (2E)-2-[(4,5-dihydro-1,3-thiazol-2-ylthio)methyl]-3-(2-thienyl) acrylate, 16: Yellow solid. Yield 
70%; m.p. 127 °C. I.R (KBr pellets cm
-1): υ 1706, 1606, 1261, 1203, 1145, 962, 730 ppm; 
1H NMR (DMSO-d6, 
400 MHz): δ 7.98 (s, 1H), δ 8.06 (s, 1H), δ 7.96 (d, J = 4.96 Hz, 1H), δ 7.63 (d, J = 3.56 Hz, 1H),  δ 7.25 (dd, J = 
3.8, 5.08 Hz, 1H), δ 4.41 (s, 2H), δ 3.77 (s, 3H), δ 3.51 (s, 3H); 
13C NMR (300 MHz, CDCl3 ): δ 167.28, 165.14, 
137.21, 135.30, 133.31, 131.12, 127.79 (2C), 122.18, 64.30, 52.43, 35.73, 30.62; MS: m/z 300.0 (M
+). 
 
   Methyl  (2E)-2-[(1,3-benzothiazol-2-ylthio) methyl]-3-(2-thienyl) acrylate, 17: White solid. Yield 72%; 
m.p. 103 °C. I.R (KBr pellets cm
-1): υ 1704, 1608, 1423, 1263, 1205, 1155, 752 ppm; 
1H NMR (DMSO-d6, 400 
MHz): δ 8.06 (d, J = 4.44 Hz, 1H), δ 8.03 (s, 1H), δ 7.95 (d, J = 4.48 Hz, 1H), δ 7.86 (d, J = 8.12 Hz, 1H), δ 7.69 
(d, J = 3.4 Hz, 1H), δ 7.49- δ 7.46 (m, 1H), δ 7.39 - δ 7.35 (m, 1H), δ 7.25 (d, J = 3.88 Hz, 1H), δ 4.67 (s, 2H), δ 
3.78 (s, 3H); 
13C NMR (300 MHz, DMSO-d6):  δ 166.53, 165.48, 152.54, 136.31, 135.26, 134.79, 132.99, 
127.98, 126.34, 124.54, 121.78, 121.17, 120.96, 52.33, 31.06; MS: m/z 348.0 (M
+). 
 
   Methyl(2E)-2-{[(5-methoxy-1,3-benzothiazol-2-yl)thio]methyl}-3-(2-thienyl)  acrylate,  18:  White solid. 
Yield 82%; m.p. 173 °C. I.R (KBr pellets cm
-1): υ 1705, 1614, 1447, 1274, 1206, 1029, 835, 709 ppm; 
1H NMR 
(DMSO-d6, 400 MHz): δ 8.0(s, 1H), δ 7.93 (d, J = 4.96 Hz, 1H), δ 7.67 (d, J = 3.28 Hz, 1H), δ 7.42 (s, 1H), δ 
7.25 (t, 1H), δ 6.93 (d, J = 13.6 Hz, 1H), δ 6.78 (dd, J = 2.2, 8.76 Hz, 1H), δ 4.53 (s, 2H), δ 3.77 (s, 3H), δ 3.75 
(s, 3H); 
13C NMR (300 MHz, DMSO-d6): δ 166.88, 163.24, 157.40, 139.25, 137.34, 136.33, 135.13, 133.28, 
128.45, 127.95, 124.16, 121.06, 120.87, 52.17, 30.63, 23.96; MS: m/z 378.0 (M
+). 
 
   Methyl(2E)-2-{[(4-phenyl-1,3-thiazol-2-yl)thio]methyl}-3-(2-thienyl) acrylate, 19: White solid. Yield 83%; 
m.p. 173 °C. I.R (KBr pellets cm
-1): υ 1708, 1608, 1265, 1203, 1033, 725 ppm; 
1H NMR (DMSO-d6, 400 MHz): 
δ 8.08 (s, 1H), δ 8.02 (s, 1H), δ 7.94 - δ 7.88  (m, 3H), δ 7.67 (d, J = 3.44 Hz, 1H), δ 7.45 (t, 2H), δ 7.36 (t, 1H), 
δ 7.23 (dd, J = 3.76, 4.88 Hz, 1H), δ 4.56 (s, 2H), δ 3.74 (s, 3H); 
13C NMR (300 MHz, DMSO-d6): δ 166.58, 
162.41, 154.43, 136.36, 134.99, 134.61, 133.47, 132.63, 128.69 (2C), 128.12, 127.96, 125.91 (2C), 121.90, 
115.16, 52.25, 31.98; MS: m/z 374.0 (M
+). 
 
  Methyl (2E)-2-{[(5-phenyl-1,3,4-oxadiazol-2-yl)thio] methyl}-3-(2-thienyl) acrylate, 20: Yellow solid. 
Yield 75%; m.p. 186 °C. I.R (KBr pellets cm
-1): υ 1712, 1612, 1467, 1272, 1209, 1193, 719, 700 ppm; 
1H NMR 
(DMSO-d6, 400 MHz): δ 8.06 (s, 1H), δ 87.99 (s, 1H), δ 7.95 - δ 7.90 (m, 2H), δ 7.69- δ 7.56 (m, 4H), δ 7.24 
(dd, J = 3.76, 4.8 Hz, 1H), δ 4.60 (s, 2H), δ 3.73 (s, 3H); 
13C NMR (300 MHz, DMSO-d6 + TFA-d): δ 166.67, 
165.90, 162.77, 136.40, 135.58, 135.32, 132.98, 132.20, 129.51, 128.30, 126.57, 123.18, 121.67, 117.09, 
113.27, 52.47, 30.86; MS: m/z 359.0 (M
+). 
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   Methyl 2E)-2-{[(4-methyl-4H-1,2,4-triazol-3-yl)thio]methyl}-3-(2-thienyl) acrylate, 21: Pale yellow solid. 
Yield 74%; m.p. 149 °C. I.R (KBr pellets cm
-1): υ 1704, 1619, 1432, 1280, 1214, 1168, 734 ppm; 
1H NMR 
(DMSO-d6, 400 MHz) δ 8.58 (s, 1H), δ 7.96 (s, 1H), δ 7.94 (d, J = 4.92 Hz, 1H), δ 7.63 (d, J = 3.52 Hz, 1H), δ 
7.24 (t, 1H), δ 4.25 (s, 2H), δ 3.68 (s, 3H), δ 3.61 (s, 3H); 
13C NMR (300 MHz, DMSO-d6): δ 166.49, 147.77, 
146.40, 136.33, 134.89, 134.33, 132.52, 127.98, 122.38, 52.22, 31.32, 30.90; MS: m/z 297.1 (M
+). 
 
   Methyl (2E)-3-(2-thienyl)-2-[(1H-1,2,4-triazol-3-ylthio)methyl] acrylate, 22: Brown solid. Yield 78%; m.p. 
120 °C. I.R (KBr pellets cm
-1): υ 1706, 1637, 1617, 1251, 1207, 705, 688 ppm; 
1H NMR (DMSO-d6, 400 MHz):  
δ 7.95 (s, 1H), δ 7.89 (d, J = 4.4 Hz, 2H), δ 7.78 (bs, 1H), δ 7.63 (d, J = 3.24 Hz, 1H), δ 7.21 (t, 1H), δ 4.27 (s, 
2H), δ 3.74 (s, 3H); 
13C NMR (300 MHz, DMSO-d6): δ 166.54, 146.37, 145.29, 138.01, 135.61, 131.85, 128.46, 
119.99, 118.76, 52.77, 33.65; MS: m/z 282.1 (M
+). 
 
   Methyl (2E)-2-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-3-(2-thienyl) acrylate, 23: White solid. Yield 
76%; m.p. 63 °C. I.R (KBr pellets cm
-1): υ 1704, 1619, 1432, 1280, 1214, 1168, 734 ppm; 
1H NMR (DMSO-d6, 
400 MHz): δ 8.04 (s, 1H), δ 7.98 (d, J = 5.0 Hz, 1H), δ 7.68 (d, J = 3.52 Hz, 1H), δ 7.26 (t, 1H), δ 4.47 (s, 2H), δ 
3.97 (s, 3H), δ 3.72 (s, 3H); 
13C NMR (300 MHz, CDCl3): δ 167.04, 153.61, 136.74, 136.21, 134.16, 131.76, 
128.03, 121.17, 52.59, 33.60, 31.64; MS: m/z 297.1 (M
+). 
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Reagents and Condition: (i) DABCO, room temperature, 80 h (ii) HBr, Con.H2SO4, methylene chloride, 5-10 
°C, 3 h  (iii) Na2CO3, methanol, room temperature, 1 h   
 
Results and Discussion 
    Compound 3 Baylis-Hillman adduct was prepared using thiophene-2- carboxaldehyde 1 and methyl acrylate 2 
as starting material without any solvent and DABCO as catalyst according the reported procedure
33. The 
structure of this intermediate was confirmed by I.R and NMR spectral analysis. The sharp absorption at 1716 
cm
-1, 1631 cm
-1, and 1438 cm
-1 in the I.R spectrum showed that compound 3 to be α, β-unsaturated ester. The 
broad absorption at 3448 cm
-1 in the I.R spectrum showed the presence of hydroxyl group. Three singlets at δ 
5.7, δ 5.9 and δ 6.3 each integrating for one proton in the 
1H NMR spectrum correspond to two vinylic protons 
and the single hydroxy methylene proton. The appearance of singlet at δ 5.7 is due to the presence of a hydroxy 
methylene group and the deshielding is due to its presence adjacent to vinylic group. Signals corresponding to 
thiophenylic protons appear around δ 6.9 and δ 7.7 and the 3-carbomethoxy protons as singlet at δ 3.7. The 
compound 3 is thus confirmed by the above spectral data. 
       The hydroxy compound 3 was converted to thienyl bromo ester 4 by tr eatm ent wit h 47%  HBr  in t he  
presence of Con.H2SO4 in MDC at rt according the reported procedure
34. It was purified in hexane solvent to 
afford a low melting solid, which was the key intermediate in synthesizing the title compounds. The conversion 
of alcohol to bromide is evident from the appearance of absorption at 723 cm
-1 and disappearance of broad 
absorption around 3448 cm
-1 in the I.R spectrum. In 
1H NMR spectrum, a singlet at δ 4.58 for two protons 
indicates the proton at the bromo methyl group and the vinylic protons appear much deshielded at δ 8.03. From 
the above data, the compound 4 is structurally confirmed. 
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      The above synthesized bromo ester 4 was treated with various thiol substituted heterocyclic compounds in 
presence of Na2CO3 and methanol to afford a series of esters (compounds 6 to 23) at rt according the reported 
procedure
35-36. Completion of the reaction was judged by TLC and the isolation of products involves simple 
workup. Crude product obtained was further purified by simple recrystalisation methods. Thio ether formation is 
evident from the absorption at 1263 cm
-1 and 1153 cm
-1 (compound 7) and the thiomethylene protons appeared 
as singlet integrating for two protons at δ 4.44. The vinyl proton of the α, β -unsaturated system were deshielded 
significantly and appeared as a singlet at δ 8.0. In the 
13C NMR spectrum, a signal at δ 166.77 correspond to the 
carbonyl, with the thiomethylene and methoxy carbons appearing at δ 52.24 and δ 28.53 respectively. The mass 
spectrum of 7 showed a molecular ion peak at m/z 293.1 (M
+), which further confirms the structure.  
       Compounds 6-23 were prepared as per the scheme 1 and their structures are presented in Table 1. The 
structures of all the compounds were confirmed by their spectral analysis, which are presented in the 
experimental section. 
 
Table 1 
Structural formulae of the synthesized compounds, 6-23 
O
O
S
S
R
 
Compound no  R 
6 
N X
7 
N
N
X
8 
N
N
N
N
H
X
9  N
N
X
CH3
10  N
NH
X
11 
N
NH
X
O
CH3
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12 
O F
F
N
NH
X
13 
N
NH
X
NO 2
14 
N
NH
X
CH3
15 
N
N
S
CH3
X
16 
N
S
X
17  N
S
X
18 
N
S
X
O
CH3
19 
N
S
X
20 
N
N
O
X
21  N
N
N
X
CH3
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22  N H
N
N
X
23 
N
N
N
N
X
C H3
 
Antimicrobial activity 
     Antimicrobial activity of all the eighteen compounds synthesized was assayed by agar well diffusion method 
as recommended by CLSI 
37 against four representative bacterial, and one fungal isolate namely S. aureus 
ATCC 25923, E. coli ATCC 25922, P. aeruginosa ATCC 27853, B. subtilis ATCC 6633, and Candida albicans 
ATCC 90028. Bacterial cultures were grown to exponential phase and plated by pour-plate method into the 150 
mm Petri dishes and allowed to settle. Wells were bored into the inoculated plate and the test compounds were 
dispensed in the wells at three concentrations such as 10 g, 100 g and 1000 g per well respectively and 
allowed for complete diffusion. Three antibacterial agents (Cefepime, Amikacin & Linezolid) were used as 
internal assay standards and 100% DMSO was used as a control. The plates were incubated for 24 hours at 
37°C. The zones of inhibition were measured using the digital Vernier’s calipers.   
            The preliminary results of antimicrobial activities indicated that only eight compounds out of eighteen 
compounds exhibited a moderate to good activity against bacterial strains, while other compounds did not exert 
any antibacterial activity. All the eighteen compounds tested against fungi did not show any antifungal activity. 
The disc concentration and their zone of inhibition of the tested compounds were tabulated as per CLSI and is 
presented in Table 2   
            Compounds which showed signifiacant activity in the preliminary screening were further tested for 
antibacterial activity by agar dilution method for MIC as per the CLSI against the clinical isolates of S. aureus 
ATCC 25923, S. aureus ATCC 43300, B. subtilis ATCC 6633, E. coli ATCC 25922, P. aeruginosa ATCC 
27853, K. pneumoniae ATCC 700603, K. pneumoniae ATCC 51503, E. cloacae 2160 P99+, E. coli J53 R6206, 
E. coli NCTC 13353 and E. coli ATCC BAA 200. All the nine compounds tested showed only Gram positive 
activity Table 3. From the activity data, it is observed that compound 22 was the most active derivative against 
Bacillus subtilis ATCC 6633 (MIC = 4 μg/mL), followed by MSSA S. aureus ATCC 25923 (MIC = 8 μg/mL) 
and MRSA S. aureus ATCC 43300 (MIC = 4 μg/mL) and the comparative activity of linezolid was 1, 4, and 2 
μg/mL respectively. Among the Gram negative clinical isolates all the tested compounds showed an MIC of 
>1024 μg/mL.        
 
Table 2  
Antimicrobial activities of the newly synthesized compounds (Zone of inhibition in mm) 
Compound 
S. aureus 
ATCC 25923 
B. subtilis 
ATCC 6633 
E. coli 
ATCC 25922 
P. aeruginosa 
ATCC 27853 
1000 g 100    g  10    g 
1000      
g  100  g  10    g 1000  g 
100 
g  10 g 1000  g 100    g 
10    
g 
15  18.96  12.32 nz 11.54 nz  nz  nz
#  nz nz 8.32  nz nz 
16  15.32 8.63  nz  13.85  nz  nz  10.52  nz nz 7.62  nz nz 
17  14.53  11.78 nz 10.93 nz  nz  nz nz  nz nz  nz  nz 
18  18.32  13.24 nz 13.64  8.54  nz 11.54  nz  nz nz  nz  nz 
19  21.32  16.75 8.32 16.54 9.85  nz  11.22 nz nz  6.35  nz nz 
21  22.43  12.53 8.64 21.36  14.53  nz  13.52  nz nz 9.54  nz nz 
22  23.52 18.65 15.35 25.60 20.66 18.45 14.35 8.6  nz  10.02  nz  nz 
23  21.65 16.32 10.52 20.35 16.35 11.32  8.32  nz  nz  11.30  nz  nz 
Linezolid 30.16  30.53  nz  nz 
Amikacin 25.42  35.13  25.23  26.37 
Cefepime 28.21  37.6  31.47  26.69 
#  -  no zone of inhibition 
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Table 3 
Minimum inhibitory concentration (MIC, g/mL) of selected compounds against Gram positive bacterial 
strains
a 
 
Compound 
S. aureus         
ATCC 25923 
S. aureus         
ATCC 43300 
B. subtilis         
ATCC 6633 
MIC g/mL MIC  g/mL MIC  g/mL 
15  64 512 256 
16  256 128  64 
17  512 512 512
18  256 128  64 
19  128 512 256 
21  64 32 16
22  8 16 4 
23  32 32 16 
Linezolid 4  2 1
Amikacin 2  128  0.5 
Cefepime 2  32  2 
 
a Disc diffusion method used to determine the MIC 
 
Conclusion 
    In conclusion, we have reported the synthesis of eighteen new thienyl acrylate compounds and evaluated their 
antibacterial activity. Among the compounds that exhibit antibacterial activity against Gram positive bacteria, 
compound 22 shows better antibacterial activity.  We conclude that further improvement of the scaffold is 
underway to increase the efficacy and specificity by structural refinements and modulation. 
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